Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biotechnology firm Capricor Therapeutics has entered into an exclusive license agreement with Cedars-Sinai Medical Center for intellectual property (IP) related to the development of exosomes technology, which is expected to have the potential to form the basis of a next generation therapeutic platform in regenerative medicine.
Subscribe to our email newsletter
As part of the deal, Capricor has been granted an exclusive world-wide license, with the right to sublicense, IP related to exosomes originating from cardiosphere-derived cells (CDCs).
The licensed technology is based upon preclinical research led by Eduardo Marban, director of the Cedars-Sinai Heart Institute and co-founder and Scientific Advisory Board chairman of Capricor.
As reported in today’s print issue of Stem Cell Reports, researchers demonstrated that exosomes extracted from the company’s CDCs prompted myocardial regeneration in pre-clinical models of ischemic heart disease.
In addition, the exosomes were shown to induce various structural and functional changes within the heart and these findings show for the first time that exosomes derived from CDCs possess regenerative capabilities and serve as proof of principle for their potential as therapeutic agents.
Capricor Therapeutics chief executive officer Linda Marban said licensing the exosome portfolio from Cedars-Sinai Medical Center is especially exciting because it allows the company to expand its regenerative medicine pipeline with a cell-free product platform that may have opportunities across various indications where inflammation, scarring, and cell death are part of the disease process.
"The unique properties of CDC-derived exosomes may allow us to develop novel cell-free therapeutics and expand our product portfolio," Marban said.
"Though it is early in the development cycle, we are excited about this new platform technology. Capricor plans to explore development of the exosome technology as a next generation regenerative medicine platform in a variety of cardiovascular and non- cardiovascular areas."